AFP and hepatocellular carcinoma: Clinical treatment responses were observed in 66.7% (n=6) of treated tumors, including: pain relief (n=3), gastrointestinal symptom relief (e.g., decreased nausea/vomiting, improved appetite, n=4), AFP marker reduction from 169 to 101 ng/mL in a hepatocellular carcinoma patient 2.5 months post-SFRT, and improvement in biliary obstruction (evidenced by decrease in bilirubin from 39.9 to 21.3 mg/dL, resolution of jaundice, and normalization of stool color, 1 month post-SFRT).